Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOQVU9)

Drug Name
Hydroxyurea Drug Info
Synonyms
Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
3657
ChEBI ID
CHEMBL467
CAS Number
CAS 127-07-1
TTD Drug ID
D07CWD
VARIDT Drug ID
DR01177
ACDINA Drug ID
D00317

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.26 0.00e+0 34/36 (94.44%) PCNA;POLE2;RPA3;...
Proteasome 2.25 0.00e+0 44/46 (95.65%) PSMA6;PSMA4;PSMA2;...
Spliceosome 2.14 0.00e+0 101/150 (67.33%) EIF4A3;PUF60;SNRPB;...
Folate biosynthesis 2.05 0.00e+0 23/26 (88.46%) AKR1B10;GGH;GCH1;...
Nucleotide excision repair 1.95 5.65e-3 40/47 (85.11%) PCNA;POLE2;RPA3;...
Mismatch repair 1.93 5.89e-3 22/23 (95.65%) PCNA;RPA3;RFC2;...
Terpenoid backbone biosynthesis 1.88 5.05e-3 18/22 (81.82%) ACAT2;IDI1;GGPS1;...
Cell cycle 1.83 9.71e-3 110/124 (88.71%) PCNA;PLK1;CDK1;...
Staphylococcus aureus infection 1.76 1.88e-2 72/95 (75.79%) C3AR1;KRT10;CFH;...
Ribosome biogenesis in eukaryotes 1.70 3.32e-2 52/108 (48.15%) NXT1;RPP30;NOP56;...
Parkinson disease 1.66 4.43e-2 176/249 (70.68%) GNAS;CALML3;COX7A1;...
Phosphatidylinositol signaling system -1.71 4.02e-2 82/97 (84.54%) PIK3R3;PLCG2;IP6K1;...
B cell receptor signaling pathway -1.71 4.33e-2 71/81 (87.65%) PIK3R3;PLCG2;NFATC1;...
Lysosome -1.71 4.25e-2 115/128 (89.84%) AP3D1;GAA;ATP6V0C;...
Glycerophospholipid metabolism -1.72 4.28e-2 71/98 (72.45%) PISD;DGKQ;CHKA;...
Transcriptional misregulation in cancer -1.73 4.45e-2 158/192 (82.29%) BAX;PBX1;NR4A3;...
Insulin resistance -1.74 4.21e-2 96/108 (88.89%) IKBKB;GSK3B;FOXO1;...
Autophagy -1.76 4.74e-2 113/169 (66.86%) MTMR14;DAPK3;RPS6KB1;...
Inositol phosphate metabolism -1.81 2.80e-2 66/73 (90.41%) PIP4K2A;SYNJ1;ITPKB;...
Porphyrin and chlorophyll metabolism -1.81 3.05e-2 23/43 (53.49%) UGT2B28;COX15;UGT2A3;...
Other glycan degradation -1.82 3.66e-2 13/18 (72.22%) MAN2B1;ENGASE;NEU1;...
Mitophagy -1.86 2.29e-2 56/68 (82.35%) ATG9A;FIS1;TAX1BP1;...
Synaptic vesicle cycle -1.93 8.72e-3 63/78 (80.77%) RAB3A;ATP6V0A4;SLC1A2;...
Type II diabetes mellitus -1.99 6.54e-3 42/46 (91.3%) CACNA1A;CACNA1C;INS;...
Mineral absorption -2.03 0.00e+0 48/60 (80%) ATP2B4;ATP1A1;ATP2B1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H